Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Strategy
MSTR
US Stock MarketDetailed Quotes
ORKA Oruka Therapeutics
- 10.940
- +0.480+4.59%
Close Mar 10 16:00 ET
- 10.520
- -0.420-3.84%
Pre 04:39 ET
409.60MMarket Cap-28.79P/E (TTM)
11.030High10.035Low225.47KVolume10.230Open10.460Pre Close2.39MTurnover0.96%Turnover RatioLossP/E (Static)37.44MShares33.00052wk High1.08P/B256.06MFloat Cap9.44052wk Low--Dividend TTM23.41MShs Float40838092.445Historical High--Div YieldTTM9.51%Amplitude9.440Historical Low10.604Avg Price1Lot Size
About Oruka Therapeutics Company
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Company Profile
SymbolORKA
Company NameOruka Therapeutics
Listing DateAug 8, 1997
CEODr. Lawrence Otto Klein, PhD
MarketNASDAQ
Employees36
Fiscal Year Ends12-31
Address855 Oak Grove Avenue,Suite 100
CityMenlo Park
ProvinceCalifornia
CountryUnited States of America
Zip Code94025
Phone1-650-606-7910
Websitehttp://www.orukatx.com
Company Executives
- Name
- Position
- Salary
- Dr. Lawrence Otto Klein, PhD
- Director, President and Chief Executive Officer
- 520.91K
- Dr. Joana Goncalves, M.D.
- Chief Medical Officer
- 317.99K
- Arjun Agarwal
- Senior Vice President, Finance and Treasurer
- --
- Dr. Samarth Kulkarni, PhD
- Chairman of the Board
- 27.74K
- Kristine M. Ball
- Independent Director
- 20.55K
- Peter Harwin
- Independent Director
- 19.18K
- Dr. Carl Dambkowski, M.D.
- Independent Director
- 16.27K
- Dr. Cameron Turtle, D.Phil.
- Independent Director
- --
- Paul T. Quinlan PhD
- General Counsel and Corporate Secretary
- 310.45K